ScholarIQanswers from OpenAlex & ORCID
David W. Boulton
ResearcherPublications, citations & collaboration network
David W. Boulton is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David W. Boulton have?
ScholarIQindexed works
David W. Boulton has 197 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David W. Boulton have?
ScholarIQcitation count
David W. Boulton has 7,268 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David W. Boulton?
ScholarIQh-index
David W. Boulton has an h-index of 45 in OpenAlex.
What is the i10-index of David W. Boulton?
ScholarIQi10-index
David W. Boulton has an i10-index of 113 in OpenAlex.
What is the ORCID of David W. Boulton?
ScholarIQorcid
The ORCID for David W. Boulton is on the source record.
What is the OpenAlex record for David W. Boulton?
ScholarIQopenalex
The OpenAlex for David W. Boulton is on the source record.
What are the most-cited papers on David W. Boulton?
ScholarIQmost cited works
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie, Subodh Verma, Kieran F. Docherty, Silvio E. Inzucchi, Inder S. Anand, Jan Bělohlávek, Michael Böhm, Chern‐En Chiang, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Mirta Díez, Jarosław Dróżdż, Andre Dukát, Junbo Ge, Jonathan G. Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta Ljungman, Béla Merkely, José Carlos Nicolau, Eileen O’Meara, Pham Nguyễn Vinh, Morten Schou, С. Н. Терещенко, Lars Køber, Mikhail Kosiborod, Anna Maria Langkilde, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon, Per Johanson, Peter J. Greasley, David W. Boulton, Olof Bengtsson, Pardeep S. Jhund, John J.V. McMurray
Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis
Karen Melissa Hallow, Gabriel Helmlinger, Peter J. Greasley, John J.V. McMurray, David W. Boulton
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Bernard J. Komoroski, N. Vachharajani, David W. Boulton, David M. Kornhauser, Margarida Geraldes, L Li, Marc Pfister
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda Morrow, Bruce R. Leslie, David W. Boulton, Agatha Ching, Frank LaCreta, Steven C. Griffen
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank LaCreta, Steven C. Griffen, David W. Boulton